Last reviewed · How we verify
Aramchol free acid tablet 300mg, bid — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Aramchol free acid tablet 300mg, bid (Aramchol free acid tablet 300mg, bid) — Galmed Research and Development, Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Aramchol free acid tablet 300mg, bid TARGET | Aramchol free acid tablet 300mg, bid | Galmed Research and Development, Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Aramchol free acid tablet 300mg, bid CI watch — RSS
- Aramchol free acid tablet 300mg, bid CI watch — Atom
- Aramchol free acid tablet 300mg, bid CI watch — JSON
- Aramchol free acid tablet 300mg, bid alone — RSS
Cite this brief
Drug Landscape (2026). Aramchol free acid tablet 300mg, bid — Competitive Intelligence Brief. https://druglandscape.com/ci/aramchol-free-acid-tablet-300mg-bid. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab